Boulder-based Array BioPharma’s loss grows to $32M

  BOULDER — Array BioPharma Inc. (Nasdaq: ARRY) missed analyst expectations by 4 cents when it posted a third-quarter loss per share of 21 cents. The cancer-research company also missed on revenue. Its $33.3 million for the quarter was a 23 percent slide from the same period last year and missed analyst expectations by nearly $4 million. Operating expenses grew year-over-year by about $2 million to $65 million. And loss from operations grew from $20 million…